Page 177 - 2019_04-Haematologica-web

Real-world results of first-line therapy in CLL
for cytogenetic testing in British Columbia,
Canada. Leuk Res. 2017;55:79-90.
33. Tam CS, O'Brien S, Plunkett W, et al. Long- term results of first salvage treatment in CLL patients treated initially with FCR (fludara- bine, cyclophosphamide, rituximab). Blood.
2014;124(20):3059-3064.
34. Burger JA, Tedeschi A, Barr PM, et al.
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425-2437.
35. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine com- pared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382-3391.
36. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007; 25(35):5616- 5623.
37. Gentile M, Shanafelt TD, Mauro FR, et al. Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. Am J Hematol. 2018;93(2):E35-E37.
38. Benjamini O, Jain P, Trinh L, et al. Second
cancers in patients with chronic lymphocyt- ic leukemia who received frontline fludara- bine, cyclophosphamide and rituximab ther- apy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56(6):1643-1650.
39. Tam CS, O'Brien S, Wierda W, et al. Long- term results of the fludarabine, cyclophos- phamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
40. Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349-1355.
41. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunothera- py in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
42. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocyt- ic leukemia. Leuk Lymphoma. 2008;49(1): 49-56.
43. Friedman DR, Magura LA, Warren HA, et al.
Statin use and need for therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(12):2295-2298.
44. Shanafelt TD, Rabe KG, Kay NE, et al. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lympho- cytic leukemia. Leuk Lymphoma. 2010;51(7):1233-1240.
45. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treat- ment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6):1095-1100.
46. Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178(3):394-402.
47. Hillmen P, Janssens A, Babu KG, et al. Health- related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with pre- viously untreated CLL. Acta Oncol. 2016;55(9-10):1115-1120.
haematologica | 2019; 104(4)
805